Answer
Concomitant neonatal Fc receptor (FcRn) blockers may lower eculizumab systemic exposure and reduce its effectiveness, requiring close monitoring for reduced effectiveness.
Sources for this answer
- Soliris 300 mg concentrate for solution for infusionAlexion Pharma UK Ltd · emc · SmPC §4.5 Interaction with other medicinal products · Version 29Document updated
Sources checked